472 related articles for article (PubMed ID: 11124228)
1. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
Voorman RL; Payne NA; Wienkers LC; Hauer MJ; Sanders PE
Drug Metab Dispos; 2001 Jan; 29(1):41-7. PubMed ID: 11124228
[TBL] [Abstract][Full Text] [Related]
2. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
3. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes.
Yao HT; Chang YW; Lan SJ; Chen CT; Hsu JT; Yeh TK
Life Sci; 2006 Nov; 79(26):2432-40. PubMed ID: 16978661
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A.
Voorman RL; Maio SM; Hauer MJ; Sanders PE; Payne NA; Ackland MJ
Drug Metab Dispos; 1998 Jul; 26(7):631-9. PubMed ID: 9660845
[TBL] [Abstract][Full Text] [Related]
8. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
Gentile DM; Verhoeven CH; Shimada T; Back DJ
J Pharmacol Exp Ther; 1998 Dec; 287(3):975-82. PubMed ID: 9864282
[TBL] [Abstract][Full Text] [Related]
9. Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A.
von Moltke LL; Greenblatt DJ; Grassi JM; Granda BW; Venkatakrishnan K; Schmider J; Harmatz JS; Shader RI
J Pharm Pharmacol; 1998 Sep; 50(9):997-1004. PubMed ID: 9811160
[TBL] [Abstract][Full Text] [Related]
10. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
11. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
Wen X; Wang JS; Backman JT; Laitila J; Neuvonen PJ
Drug Metab Dispos; 2002 Jun; 30(6):631-5. PubMed ID: 12019187
[TBL] [Abstract][Full Text] [Related]
12. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
Wen X; Wang JS; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2002 Jan; 57(11):799-804. PubMed ID: 11868802
[TBL] [Abstract][Full Text] [Related]
13. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
Yamazaki H; Shimada T
Arch Biochem Biophys; 1997 Oct; 346(1):161-9. PubMed ID: 9328296
[TBL] [Abstract][Full Text] [Related]
14. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
Giancarlo GM; Venkatakrishnan K; Granda BW; von Moltke LL; Greenblatt DJ
Eur J Clin Pharmacol; 2001 Apr; 57(1):31-6. PubMed ID: 11372587
[TBL] [Abstract][Full Text] [Related]
15. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
Tang C; Shou M; Mei Q; Rushmore TH; Rodrigues AD
J Pharmacol Exp Ther; 2000 May; 293(2):453-9. PubMed ID: 10773015
[TBL] [Abstract][Full Text] [Related]
16. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes.
Barecki ME; Casciano CN; Johnson WW; Clement RP
Drug Metab Dispos; 2001 Sep; 29(9):1173-5. PubMed ID: 11502723
[TBL] [Abstract][Full Text] [Related]
18. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A.
Voorman RL; Maio SM; Payne NA; Zhao Z; Koeplinger KA; Wang X
J Pharmacol Exp Ther; 1998 Oct; 287(1):381-8. PubMed ID: 9765359
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
Grimm SW; Dyroff MC
Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
[TBL] [Abstract][Full Text] [Related]
20. Effects of propofol on human hepatic microsomal cytochrome P450 activities.
McKillop D; Wild MJ; Butters CJ; Simcock C
Xenobiotica; 1998 Sep; 28(9):845-53. PubMed ID: 9764927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
